one dollaKEY TAKEAWAY: GlaxoSmithKline’s chief executive has warned that cheap money has increased the risk of companies making “poor choices” in mergers and acquisitions and questioned the “stretched” valuations of recent pharmaceuticals deals.  More than $460bn of deals have been struck across the pharma and biotech sectors since the start of last year — the busiest period of M&A on record.  So what effect is this going to have on DTC marketing and drug marketing in general?  Cuts and more cuts.